Disease control of patients with newly screening-detected hyperuricemia: A retrospective cohort study of health insurance claims and medical check-up data

Disease control of patients with newly screening-detected hyperuricemia: A retrospective cohort study of health insurance claims and medical check-up data - Disease control of patients with newly screening-detected hyperuricemia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039985

Enrollment

15000

Registered

2020-03-30

Start date

2020-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout, hyperuricemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subjects who have a serum uric acid level of 8.0 mg/dL or more at least one during the medical check-ups between April 2013 and March 2016 2. Subjects for whom eGFR data are available on the same day when the serum uric acid level of 8.0 mg/dL or more for the first time (index date) 3. Subjects for whom serum uric acid level are available within 1 year after the index date (follow up date) 4. Subjects over the age of 18 on the index date 5. Subjects who have consecutively registered in the health insurance claims database for at least 12 months before the index month and for 24 months after the follow up date

Exclusion criteria

Exclusion criteria: 1. Patients who identified gout or asymptomatic hyperuricemia during the index period 2. Patients who received prescriptions of urate-lowering therapy during the index period 3. Patients who identified malignant neoplasms during the index period

Design outcomes

Primary

Measure	Time frame
1. Disease control status (Association between prescription of urate-lowering therapy, onset of gouty arthritis, and serum uric acid level after 1-year) 2. Disease burden for disease control status (frequency of gouty arthritis)	—

Countries

Japan

Contacts

Public ContactRuriko Koto

Teijin Pharma Limited Medical Science Department

tpm-com@umin.ac.jp03-3506-4140

Outcome results